Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.
Noord Holland Michiels Van Netherlands Cancer Institute Concurrent Frontline Nivolumab And Gemcitabine Cisplatin Urothelial Carcinoma Checkmate 901 Study
Source: onclive.com